Trial · NCT02543801
A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip and Knee Arthroplasty
NCT02543801, Phase 4, Completed, Kootenai Health; results first posted 2019-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip and Knee Arthroplasty. Trials, record NCT02543801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02543801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip and Knee Arthroplasty
- NCT number
- NCT02543801
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 239 participants, actual
- Lead sponsor
- Kootenai Health
- Conditions
- Total Hip and Knee Arthroplasty
- Interventions
- Liposomal Bupivacaine, Ropivacaine, Bupivacaine, Clonidine, Ketorolac, Epinephrine
- First posted
- 2015-09-07
- Last updated
- 2019-10-18
- Results first posted
- 2019-10-18
- Limitations and caveats
- Anesthesia (general or spinal) followed patient preference and not dictated by protocol.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Score | Starting post operatively and then every four hours up to 48 hours | Self-reported pain score 0-10 (0=no pain - 10=worst possible pain experienced) and higher scores indicate a worse outcome Pain scores, collected every 4 hours per hospital care standards, were averaged (post-operatively up to 48 hours) to obtain individual mean pain scores and a mean score for the group was then calculated. |
| Secondary | Narcotic Consumption | Starting immediately post operatively up to 48 hours | Total amount of narcotics administered as calculated in oral morphine equivalent dose immediate post operatively up to 48 hours. |
| Secondary | Length of Stay | Start of surgery to hospital discharge up to 140 hours | Measured in hours |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Score | Starting post operatively and then every four hours up to 48 hours | score on a scale | MEAN | |
| SECONDARY | Narcotic Consumption | Starting immediately post operatively up to 48 hours | morphine equivalents | MEAN | |
| SECONDARY | Length of Stay | Start of surgery to hospital discharge up to 140 hours | Hours | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Score | Hip Cohort Liposomal Bupivacaine | 3.78 | Standard Deviation 2.22 | score on a scale | |
| Pain Score | Hip Cohort Ropivacaine | 3.85 | Standard Deviation 2.01 | score on a scale | |
| Pain Score | Knee Cohort Liposomal Bupivacaine | 3.3 | Standard Deviation 2.0 | score on a scale | |
| Pain Score | Knee Cohort Ropivacaine | 3.4 | Standard Deviation 2.3 | score on a scale | |
| Narcotic Consumption | Hip Cohort Liposomal Bupivacaine | 48.8 | Standard Deviation 22.9 | morphine equivalents | |
| Narcotic Consumption | Hip Cohort Ropivacaine | 57.4 | Standard Deviation 21.8 | morphine equivalents | |
| Narcotic Consumption | Knee Cohort Liposomal Bupivacaine | 52.2 | Standard Deviation 28.4 | morphine equivalents | |
| Narcotic Consumption | Knee Cohort Ropivacaine | 50.0 | Standard Deviation 22.0 | morphine equivalents | |
| Length of Stay | Hip Cohort Liposomal Bupivacaine | 33.8 | Standard Deviation 48.24655 | Hours | |
| Length of Stay | Hip Cohort Ropivacaine | 50.3 | Standard Deviation 48.41333 | Hours |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hip Cohort Liposomal Bupivacaine | 61 | |
| Overall Study | STARTED | Hip Cohort Ropivacaine | 60 | |
| Overall Study | STARTED | Knee Cohort Liposomal Bupivacaine | 59 | |
| Overall Study | STARTED | Knee Cohort Ropivacaine | 59 | |
| Overall Study | COMPLETED | Hip Cohort Liposomal Bupivacaine | 60 | |
| Overall Study | COMPLETED | Hip Cohort Ropivacaine | 58 | |
| Overall Study | COMPLETED | Knee Cohort Liposomal Bupivacaine | 59 | |
| Overall Study | COMPLETED | Knee Cohort Ropivacaine | 59 | |
| Overall Study | NOT COMPLETED | Hip Cohort Liposomal Bupivacaine | 1 | |
| Overall Study | NOT COMPLETED | Hip Cohort Ropivacaine | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Hip Cohort Liposomal Bupivacaine | 0 | 60 |
| Total, all-cause mortality | Hip Cohort Ropivacaine | 0 | 58 |
| Total, all-cause mortality | Knee Cohort Liposomal Bupivacaine | 0 | 59 |
| Total, all-cause mortality | Knee Cohort Ropivacaine | 0 | 59 |
| Total, other adverse events | Hip Cohort Liposomal Bupivacaine | 0 | 60 |
| Total, other adverse events | Hip Cohort Ropivacaine | 0 | 58 |
| Total, other adverse events | Knee Cohort Liposomal Bupivacaine | 0 | 59 |
| Total, other adverse events | Knee Cohort Ropivacaine | 0 | 59 |
| Total, serious adverse events | Hip Cohort Liposomal Bupivacaine | 0 | 60 |
| Total, serious adverse events | Hip Cohort Ropivacaine | 0 | 58 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02543801
GET https://conductscience.org/api/trials/v1/NCT02543801/registered